Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects

Next Previous
X
Search
Trial Profile

Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary)
  • Indications Congenital heart defects
  • Focus Registrational; Therapeutic Use
  • Acronyms RUBATO
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 29 Aug 2022 Primary endpoint (Change in peak VO2 (oxygen uptake)) has not been met, as per results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 29 Aug 2022 Results (n=137) assessing the efficacy and safety of macitentan in Fontan-palliated patients over 52 weeks, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 05 Aug 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top